Exelixis’ Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/7/2026

1. SPCX
2. CRNX
3. VRTX
4. WMT
5. LMT
6. RXST
7. SPY
8. RIVN
9. SPGI
10. AGIO

Go back to Exelixis’ Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma

Exelixis (EXEL) PT Raised to $35 at SunTrust Robinson Humphrey

October 16, 2017 11:16 AM EDT

SunTrust Robinson Humphrey raised its price target on Exelixis (NASDAQ: EXEL) to $35.00 (from $33.00) while maintaining a Buy rating.

... More